Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.99 AUD | +2.64% |
|
+7.64% | -15.94% |
28/05 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
27/05 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.94% | 177.16Cr | |
+63.45% | 86TCr | |
+39.35% | 63TCr | |
-4.61% | 36TCr | |
+17.54% | 32TCr | |
+8.05% | 30TCr | |
+5.56% | 23TCr | |
+16.30% | 23TCr | |
+14.33% | 18TCr | |
+1.88% | 16TCr |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Announces Cessation of Graeme Bruce Howie as Director